托珠单抗治疗巨细胞动脉炎:单中心NHS经验及影像学评估
该单中心真实世界研究纳入22例接受托珠单抗(TCZ)治疗的巨细胞动脉炎(GCA)患者,收集体温、生活质量及治疗相关并发症数据,并评估超声和18FDG-PET-CT影像学变化。结果显示TCZ疗效良好且安全性可接受,超声和FDG-PET/CT影像学均有改善。
要点
- TCZ治疗GCA可减少激素用量并改善生活质量。
- 超声颞动脉Halo评分从11降至0,腋动脉评分稳定。
- FDG-PET/CT总血管评分从11.5降至6.5。
核心结论
- TCZ在GCA中显示出良好疗效和可接受的安全性,并伴超声和FDG-PET/CT影像学改善。
研究设计与样本
- 单中心NHS真实世界研究,纳入22例连续接受TCZ治疗的GCA患者,收集体温、生活质量及治疗相关并发症数据。
主要发现
- 22例GCA患者中10例颅型、10例大血管型、2例混合型,TCZ启动前中位病程58.5周(范围1-370周)。
- 50%患者因难治、36%因缺血、14%因复发启动TCZ;中位随访43周(范围12-52周)。
- 2例因严重不良事件停用TCZ;4例停用泼尼松龙,11例需要≤2.5 mg,2例需要2.5-5 mg,5例需要≥5 mg每日泼尼松龙。
- 生活质量改善50%;38个动脉节段总超声Halo厚度下降,颞动脉Halo评分中位数从11降至0,腋动脉Halo评分保持稳定。
- FDG-PET/CT总血管评分中位数从11.5降至6.5。
临床怎么用
- TCZ可用于难治、缺血或复发GCA患者,治疗中可减少泼尼松龙剂量并改善生活质量。
- 超声和FDG-PET/CT可用于GCA治疗过程中的影像学监测。
局限性
- 单中心真实世界研究,样本量22例,FDG-PET/CT治疗前数据仅4例可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tocilizumab (TCZ), an IL-6 receptor blocker, is approved for relapsing, refractory giant cell arteritis (GCA). We report real-life clinical experience with TCZ in GCA including assessment of responses on imaging (ultrasound (US) and 18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomography (18FDG-PET-CT)) during the first year of treatment. We included 22 consecutive patients with GCA treated with TCZ where EULAR core data set on disease activity, quality of life (QoL) and treatment-related complications were collected. Pre-TCZ US and 18FDG-PET/CT findings were available for 21 and 4 patients, respectively, where we determined the effect on US halo thickness, temporal and axillary artery Southend Halo Score and Total Vascular Score on 18FDG-PET-CT. The 22 patients with GCA (10 cranial, 10 large vessel, 2 both) had a median disease duration of 58.5 (range, 1-370) weeks prior to initiation of TCZ. Half had used prior conventional synthetic disease-modifying antirheumatic drug (csDMARDs). TCZ was initiated for refractory (50%), ischaemic (36%) or relapsing (14%) disease. Median follow-up was 43 (12-52) weeks. TCZ was discontinued due to serious adverse events (SAEs) in two patients. On treatment with TCZ, 4 discontinued prednisolone, 11 required doses ≤2.5 mg, 2 required daily dose of 2.5-5 mg and 5 needed prednisolones ≥5 mg daily. QoL improved by 50%. Total US halo thickness decreased in 38 arterial segments, median temporal artery Halo Score decreased from 11 to 0, axillary artery Halo Score remained stable. Median Total Vascular Score on FDG-PET/CT reduced from 11.5 to 6.5. In our experience, TCZ showed an excellent response with acceptable safety in GCA, with improvement on US and FDG-PET/CT imaging.
引用
- Sebastian A, Kayani A, Prieto-Pena D, et al. Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool. RMD Open. 2020. PMID: 33161376. doi:10.1136/rmdopen-2020-001417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。